Ann: Imugene Appoints Kim Drapkin as Non-Executive Director, page-73

So if I might pose a genuine question ~ why do we need a director with mid cap investor credentials now?
Don’t we need a director with extensive experience in the commercialisation of IP in the bio space who brings a wealth of knowledge of the optimisation of medical developments and interaction with large Pharma? Seems to me that once the trials deliver more data that we assume show promise, that the company moves into the initial commercialisation phase. I struggle to see the attraction other than it positioning the company to capital raise as some have suggested and hence the focus on mid cap investor market being the current market for the company. This will be most interesting as I wonder if this appointment should have been far more strategic and perhaps with a more prominent figure given the time between trial results. Just my observations.